Both miR-15 and miR-16 are considered as tumor suppressors that could be used for therapy of inhibiting BCL2-, CCND1-, and CCND2-overexpressing tumors, e.g., chronic lymphocytic leukemia, breast cancer, prostate, and lung cancer [4, 7, 9, 11, 12]. The gene discussed is BCL2; the disease is breast carcinoma.